Royal Bank of Canada
PEAR

Royal Bank of Canada’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Royal Bank of Canada’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,266
Closed -$1K – 7982
2023
Q1 		$1K Sell
4,266
-7,179
-63% -$6.49K ﹤0.01% 6994
2022
Q4 		$14K Buy
11,445
+8,525
+292% +$17.9K ﹤0.01% 6439
2022
Q3 		$6K Buy
2,920
+2,437
+505% +$4.13K ﹤0.01% 6693
2022
Q2 		$1K Buy
+483
New +$1.89K ﹤0.01% 7279

Royal Bank of Canada's PEAR Position: Q2 2023 in Review

Royal Bank of Canada sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 4,266 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in PEAR in Q2 2022 and held it in 4 quarters. The position peaked at $14K in Q4 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

  • Royal Bank of Canada reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 4,266 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $1K.
  • Royal Bank of Canada first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2022 and held it in 4 quarters.
  • Royal Bank of Canada's Pear Therapeutics, Inc. Class A Common Stock position peaked at $14K in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.